Supplementary data: A real-world comparison of the clinical and economic utility of OVA1 and CA125 in assessing ovarian tumor malignancy risk

These are peer-reviewed supplementary materials for the article 'A real-world comparison of the clinical and economic utility of OVA1 and CA125 in assessing ovarian tumor malignancy risk' published in the Journal of Comparative Effectiveness Research.Appendix Table 1: CodingAim: This largest-of-its-kind study evaluated the clinical utility of CA125 and OVA1, commonly used as ovarian tumor markers for assessing the risk of malignancy. The research focused on the ability and utility of these tests to reliably predict patients at low risk for ovarian cancer. Clinical utility endpoints were 12-monthmaintenance of benign mass status, reduction in gynecologic oncologist referral, avoidable surgical intervention and associated cost savings. Materials & methods: This was a multicenter retrospective review of data from electronic medical records and administrative claims databases. Patients receiving a CA125 or OVA1 test between October 2018 and September 2020 were identified and followed for 12 months using site-specific electronic medical records to assess tumor status and utilization outcomes. Propensity score adjustment was used to control for confounding variables. Payer allowed amounts from Merative MarketScan Research Databases were used to estimate 12-month episode-of-care costs per patient, including surgery and other interventions. Results: Among 290 low-risk OVA1 patients, 99.0% remained benign for 12 months compared with 97.2% of 181 low-risk CA125 patients. The OVA1 cohort exhibited 75% lower odds of surgical intervention in the overall sample of patients (Adjusted OR: 0.251, p ≤ 0.0001), and 63% lower odds of gynecologic oncologist utilization among premenopausal women (Adjusted OR: 0.37, p = 0.0390) versus CA125. OVA1 demonstrated significant savings in surgical interventions ($2486, p ≤ 0.0001) and total episode-of-care costs ($2621, p ≤ 0.0001) versus CA125. Conclusion: This study underscores the utility of a reliably predictive multivariate assay for assessing ovarian cancer risk. For patients assessed at low risk of ovarian tumor malignancy, OVA1 is associated with a significant reduction in avoidable surgeries and substantial cost savings per patient. OVA1 is also associated with a significant reduction in subspecialty referrals for low-risk premenopausal patients.

本数据集为发表于《比较疗效研究杂志》上的文章《OVA1与CA125在评估卵巢肿瘤恶变风险临床及经济效用中的实际比较》的同行评审补充材料。附录表1：编码目标：此项同类研究中规模最大的研究评估了CA125和OVA1的临床效用，二者常作为卵巢肿瘤标志物用于评估恶变风险。研究着重于这些检测在可靠预测卵巢癌低风险患者方面的能力和效用。临床效用终点包括维持良性肿块状态12个月、减少妇科肿瘤学家转诊、避免不必要的手术干预及其相关成本节约。研究方法：本研究是一项多中心回顾性审查，分析了电子病历和行政索赔数据库中的数据。确定了在2018年10月至2020年9月期间接受CA125或OVA1检测的患者，并使用特定地点的电子病历对肿瘤状态和利用结果进行了为期12个月的跟踪研究。采用倾向得分调整以控制混杂变量。使用Merative MarketScan研究数据库中支付方允许的金额来估算每位患者的12个月治疗成本，包括手术和其他干预措施。结果：在290名低风险OVA1患者中，99.0%在12个月内保持良性状态，而181名低风险CA125患者的良性率为97.2%。与CA125相比，OVA1组在总体患者样本中的手术干预概率降低了75%（调整OR：0.251，p ≤ 0.0001），在绝经前女性中妇科肿瘤学家利用概率降低了63%（调整OR：0.37，p = 0.0390）。OVA1在手术干预（2486美元，p ≤ 0.0001）和总治疗成本（2621美元，p ≤ 0.0001）方面显示出显著的节约。结论：本研究强调了可靠预测的多变量检测在评估卵巢癌风险中的效用。对于评估为卵巢肿瘤恶变低风险的患者，OVA1与可避免手术的显著减少和每位患者显著的成本节约相关。OVA1还与低风险绝经前患者专科转诊的显著减少相关。